Journal of Population Therapeutics & Clinical Pharmacology

RESEARCH ARTICLE
DOI: 10.53555/jptcp.v30i3.3836

BALANCING INNOVATION AND ETHICS: THE ROLE OF AI IN CANCER RESEARCH AND CLINICAL PRACTICE

N T Pramathesh Mishra[1*], Shweta Mishra[1], Parul Mishra[1], Preeti Singh[1], Preeti[2], Alpa Verma[3], Shristi Mishra[4], Shalini Singh[5]

[1*]Department of Pharmacology, Hygia College of Pharmacy, Lucknow, Uttar Pradesh, India
[2]Department of Pharmacology, BBD University, Lucknow, Uttar Pradesh, India
[3]Department of Pharmaceutical Chemistry, B N College of Pharmacy, Lucknow, Uttar Pradesh, India
[4]Department of Pharmaceutics, Samarpan College of Pharmacy, Lucknow, Uttar Pradesh, India
[5]Department of Pharmaceutics, Goel Institute of Pharmaceutical Sciences, Lucknow, Uttar Pradesh, India

***Corresponding Author:** N T Pramathesh Mishra
*Department of Pharmacology, Hygia College of Pharmacy, Lucknow, Uttar Pradesh, India,
Email: mishrant@hygia.in

Abstract
Advancements in Artificial Intelligence (AI) have transformed the landscape of oncology, offering unprecedented opportunities for improved cancer research and clinical care. However, this evolution requires a delicate balance between innovation and ethical considerations. This abstract explores the intricate interplay between innovation and responsibility in using AI within oncology. The integration of AI technologies in oncology presents promising avenues, such as precision medicine, early detection, and personalized treatment strategies. Nevertheless, ethical challenges loom large, including biases in AI algorithms, concerns about transparency and accountability, safeguarding patient privacy, and ensuring informed consent. This underscores the necessity for a proactive approach to reconciling innovation with ethical imperatives. It emphasizes the pivotal role of interdisciplinary collaboration among healthcare professionals, technologists, ethicists, policymakers, and patients. Clear ethical guidelines and continuous assessments are vital to align AI advancements with ethical principles, ensuring that innovation in oncology is ethically grounded. In conclusion, the constructive collaboration between innovation and ethics is fundamental in shaping the future of AI in oncology. A conscientious approach to AI implementation, underpinned by ethical frameworks, is imperative. This abstract advocates for a culture of responsible AI development and deployment in oncology, aiming to maximize the transformative potential of AI while preserving the ethical fabric of healthcare.

Keywords: Oncology, Artificial Intelligence (AI), Ethical Considerations, Innovation, Responsible Deployment

Introduction

The landscape of cancer research and clinical practice has been revolutionized by the rapid integration of Artificial Intelligence (AI). This burgeoning technology has swiftly proved itself to be a pivotal force, reshaping the way we approach the detection, treatment, and management of cancer. The

application of AI-driven tools and algorithms has shown immense promise in hastening diagnoses, personalizing treatment plans, and improving patient outcomes.[1, 2, 3]

However, as we venture deeper into this era of innovation, it becomes increasingly vital to navigate the intricate intersection between progress and ethical responsibility. The transformative potential of AI in oncology must be harmonized with a steadfast commitment to upholding ethical principles. Balancing the allure of innovation with the moral imperatives of patient privacy, fairness, transparency, and equity is essential to harnessing the full potential of AI while safeguarding the well-being and rights of individuals undergoing cancer care. This delicate equilibrium between technological advancement and ethical considerations stands as the linchpin in ensuring that AI's evolution in cancer research and clinical practice is still both impactful and ethically sound.[4, 5]

Table 1: Historical Progression of AI Applications in Oncology: [6-10]

Stage	**Key Milestones**
Early Stages (1950s-1980s)	- First conceptualization of AI and its potential in medicine (1950s-1960s).
	- Early experimentation with AI algorithms in medical imaging and diagnostics (1970s-1980s).
Emergence of Expert Systems (1980s-1990s)	- Expert systems like MYCIN were developed for medical decision-making (1982).
	- Exploration and development of AI algorithms for medical diagnosis and treatment planning (Late 1980s-1990s).
Advancements in Machine Learning (1990s-2000s)	- Rise of machine learning techniques in medical research (1990s).
	- Introduction of Support Vector Machines (SVMs) for cancer classification (1998).
	- Increased utilization of machine learning for image analysis in oncology (Early 2000s).
Rise of Deep Learning (2010s-Present)	- Rapid progress in deep learning techniques like CNNs and RNNs (2010s).
	- Breakthroughs in deep learning-based tumor detection and segmentation in medical images (2016).
	- Ongoing advancements in AI-driven precision medicine and personalized cancer treatment strategies.

Transforming Diagnosis, Treatment, and Patient Care:

1. **Diagnosis:** AI-powered algorithms analyze vast amounts of medical data, such as imaging scans (like MRI, CT, or X-ray images) and pathology slides, assisting radiologists and pathologists in detecting anomalies. These algorithms often exhibit high accuracy and speed, aiding in the early and precise diagnosis of various conditions, including cancer. For instance, AI systems can detect subtle patterns or abnormalities in medical images that might be overlooked by human eyes, enabling timely and more accurate diagnoses.[12, 13]
2. **Treatment Planning:** AI assists in developing personalized treatment plans by analyzing patient data, including genetic information, medical history, and treatment outcomes. This enables oncologists to tailor therapies that are more effective and specific to an individual's condition, potentially minimizing side effects and improving overall outcomes.[14, 15]
3. **Patient Care:** AI-driven applications streamline administrative tasks, allowing healthcare providers to focus more on direct patient care. Chatbots and virtual assistants equipped with AI provide patients with immediate responses to queries, schedule appointments, and offer guidance on managing their health conditions, enhancing patient engagement and satisfaction.[16]

AI-Driven Tools Enhancing Clinical Workflows:[17-19]

1. **AI-Based Imaging Analysis:** Systems like CAD (Computer-Aided Diagnosis) analyze medical images to show and highlight potential areas of concern, aiding radiologists in interpreting images more efficiently and accurately.
2. **Clinical Decision Support Systems:** These systems supply real-time recommendations to healthcare providers based on patient data and set up medical guidelines. They aid in choosing the best treatment plans or suggesting further diagnostic tests, improving clinical decision-making.
3. **Natural Language Processing (NLP) in Electronic Health Records (EHR):** AI-driven NLP extracts valuable insights from unstructured data within EHR systems, converting free-text notes into structured data, enabling easier access to patient information, and supporting clinical decision-making.
4. **Predictive Analytics:** AI algorithms analyze patient data to predict disease progression, potential complications, or response to specific treatments, aiding healthcare providers in proactive and preventive care.

Ethical Frameworks in Cancer Research and AI Integration

Ethical frameworks play a pivotal role in guiding the integration of Artificial Intelligence (AI) into the realm of oncology, ensuring that technological advancements align with established ethical principles. In the landscape of cancer research, the integration of AI raises crucial ethical considerations. Central to these frameworks are principles of beneficence, non-maleficence, autonomy, justice, and transparency. Beneficence underscores the importance of using AI to maximize patient benefits, such as improved diagnostics, personalized treatments, and enhanced patient care. Simultaneously, the principle of non-maleficence emphasizes the need to minimize potential harm, including the risks of biases in AI algorithms, mistaken diagnoses, or breaches of patient confidentiality. Moreover, the ethical integration of AI in oncology demands a profound respect for patient autonomy. [21, 22, 23]

This involves transparent communication about the use of AI tools, ensuring patients understand the role of technology in their diagnosis and treatment. Respect for patient autonomy extends to the crucial aspect of obtaining informed consent, allowing individuals to make knowledgeable decisions about the use of their data in AI-driven analyses. Privacy and data security form critical pillars within these ethical frameworks. The vast amount of sensitive patient data used to train AI algorithms needs stringent measures to safeguard confidentiality. Striking a balance between data accessibility for research and protecting patient privacy is still a paramount ethical challenge. Ensuring anonymization, encryption, and secure data storage are imperative to keep patient trust and confidentiality. Furthermore, fostering a sense of justice in AI integration involves ensuring fair access to AI-driven advancements in cancer research and clinical care.[24, 25]

It entails addressing disparities in healthcare access and resource distribution. While considering the ethical implications of AI adoption across diverse populations. These ethical frameworks evolve alongside technological advancements, requiring continuous assessment and adaptation. Regular ethical evaluations, interdisciplinary collaborations, and stakeholder engagements are essential to navigate the dynamic landscape of AI integration in oncology while upholding ethical integrity. In summary, ethical considerations surrounding AI integration in cancer research emphasize the principles of beneficence, non-maleficence, patient autonomy, justice, and data security. These frameworks strive to harness the potential of AI-driven innovations while ensuring patient welfare, privacy, and fair access to advanced healthcare solutions.[26]

Identification of Ethical Challenges Associated with AI Adoption:

One primary challenge involves the ethical implications of biases embedded within AI algorithms. AI systems learn from historical data, which might reflect existing biases in healthcare practices. Addressing these biases becomes imperative to ensure fair and unbiased decision-making in patient care. Additionally, transparency in AI algorithms poses a significant challenge. The opacity of certain AI models and their decision-making processes raises concerns about understanding, confirming, and

explaining the outcomes derived from these systems. This lack of transparency can hinder trust among healthcare professionals and patients.[26, 27]

Analysis of Ethical Dilemmas:
Ethical dilemmas arise in ensuring accountability for AI-driven decisions in healthcare. Finding responsibility when an AI system supplies a diagnosis or treatment recommendation requires supplying clear lines of accountability between healthcare providers, developers, and regulatory bodies. Moreover, the ethical implications of data privacy and security in AI adoption persist as a dilemma. While using vast amounts of patient data fuels AI advancements, keeping patient privacy and data security becomes challenging, especially with the risk of unauthorized access or breaches. [28]

Addressing Biases, Transparency, and Accountability in AI Algorithms:
To mitigate biases, efforts should focus on developing and deploying AI models that undergo rigorous evaluation and testing to find and rectify biases. This includes employing diverse datasets and involving multidisciplinary teams to ensure a comprehensive assessment of potential biases. Moreover, promoting transparency in AI algorithms requires designing systems that supply explanations for their decisions, ensuring interpretability for clinicians and patients. Adopting standardized guidelines and regulations can set up accountability frameworks outlining responsibilities among stakeholders involved in AI healthcare solutions.[29, 30]
Overall, showing and addressing these ethical challenges in AI adoption needs collaborative efforts among researchers, clinicians, ethicists, policymakers, and technology developers. Resolving these dilemmas is crucial to fostering trust, ensuring fairness, and maximizing the benefits of AI while upholding ethical standards in oncology and healthcare at large.[31]

Table 2: Regulatory perspectives and suggestions for refining guidelines in AI implementation within healthcare:[32-35]

Regulatory Perspectives	Details
Existing Frameworks	Existing regulatory frameworks, such as HIPAA in the US or GDPR in the EU, govern data privacy and security in healthcare. Additionally, regulatory bodies like the FDA (Food and Drug Administration) oversee the approval of AI-based medical devices and software. However, there might be gaps in addressing the specific challenges posed by AI in healthcare.
Challenges	Challenges include the lack of standardized regulations tailored explicitly for AI algorithms, especially concerning their complexity and dynamic nature. Difficulty in ensuring transparency, interpretability, and accountability of AI systems poses regulatory challenges. Ensuring patient data privacy amidst AI use is also a significant concern.
Suggestions for Refinement	Refining guidelines involves creating specialized regulatory frameworks that specifically address the unique aspects of AI in healthcare. This includes developing clear criteria for evaluating and approving AI algorithms, ensuring transparency and interpretability in their functioning. Enhanced collaboration between regulatory bodies, healthcare professionals, AI developers, and ethicists is essential to update regulations in line with technological advancements. Ethics boards could be proved to assess AI systems' ethical implications before deployment. Regular updates and adaptability of regulations to keep pace with evolving technology are crucial.

Ethical AI Implementation

1. **Ethical Risk Mitigation Strategies:** Proposed strategies focus on addressing biases in AI algorithms used in oncology, ensuring transparency and interpretability of AI decisions, and setting up robust data privacy measures. Techniques like regular algorithm auditing, diversifying datasets to reduce biases and developing explainable AI models aid in ethical risk mitigation. Additionally, implementing stringent data encryption and access controls safeguards patient privacy.[36]
2. **Interdisciplinary Collaboration:** The importance of interdisciplinary collaboration emerges as a fundamental aspect of ethical AI implementation. Collaborative efforts among healthcare professionals, data scientists, ethicists, policymakers, and technology experts enable a comprehensive understanding of both the clinical nuances and ethical implications of AI in oncology. This collaboration ensures that ethical considerations are embedded in the development and deployment of AI technologies.[37]
3. **Stakeholder Involvement:** Engaging various stakeholders, including patients, advocacy groups, regulatory bodies, and industry partners, is critical. Involving patients and advocacy groups in the AI development process ensures that patient perspectives and concerns are considered. Collaboration with regulatory bodies helps align AI implementations with established ethical guidelines and regulations. Industry partnerships ease adherence to best practices and ethical standards throughout the AI lifecycle.[38]
4. **Education and Ethical Guidelines:** Promoting education and awareness among healthcare professionals and AI developers about ethical guidelines and best practices fosters a culture of ethical AI use. Establishing clear ethical guidelines and frameworks specific to AI applications in oncology serves as a guiding beacon for practitioners and developers, ensuring ethical considerations are integrated into every stage of AI development and deployment.[39]
5. **Continuous Evaluation and Adaptation:** Implementing a system of continuous evaluation and adaptation of AI systems is vital. Regular assessment of AI algorithms for biases, ethical implications, and clinical efficacy, coupled with periodic updates to ethical guidelines, ensures that AI technologies evolve responsibly to meet ethical standards and align with advancements in oncology and technology.[40]

Future Directions in AI for Cancer Research and Clinical Practice: [41-44]

1. **Precision Oncology:** AI will play a pivotal role in advancing precision oncology by analyzing extensive genomic data to find personalized treatment options. Predictive models using AI will aid in figuring out optimal therapies tailored to individual patient profiles, enhancing treatment effectiveness.
2. **Early Detection and Diagnosis:** AI algorithms will further refine their ability to detect subtle patterns in medical imaging, enabling earlier and more correct cancer diagnoses. This will lead to improved prognoses and better patient outcomes by starting treatments at earlier stages.
3. **Drug Discovery and Development:** AI-driven algorithms will hasten the drug discovery process by analyzing vast datasets and predicting potential drug candidates. This will streamline the identification of novel therapies and accelerate the development of targeted cancer treatments.
4. **Clinical Decision Support Systems:** Enhanced AI-powered clinical decision support systems will aid healthcare professionals by supplying real-time insights and evidence-based recommendations. These systems will aid in treatment planning, perfecting resource allocation, and improving patient care pathways.

Ethical Considerations in Advancing AI Technologies: [45, 46]

1. **Bias and Fairness:** Mitigating biases inherent in AI algorithms stay critical. Efforts to ensure fairness and mitigate biases, particularly in AI models used for patient care, must continue to evolve. Ethical guidelines should address the fairness and equity concerns related to AI-driven decision-making.
2. **Transparency and Accountability:** Ensuring transparency in AI algorithms and their decision-making processes is imperative. Ethical frameworks should emphasize the need for AI systems to

supply understandable explanations for their recommendations, allowing clinicians and patients to comprehend and trust AI-driven decisions.

3. **Data Privacy and Security:** Stricter measures for safeguarding patient data privacy in AI applications are crucial. Ethical guidelines must emphasize robust data encryption, secure storage, and strict access controls to protect patient confidentiality amidst the use of large datasets.
4. **Informed Consent and Patient Autonomy:** Upholding patient autonomy and ensuring informed consent regarding AI-driven treatments and data utilization are ethical imperatives. Patients should be informed about AI's role in their care and have the autonomy to consent or refuse AI-assisted treatments or data sharing.

Conclusion

In the realm of cancer research and clinical care, the constructive collaboration between innovation and ethics in employing AI appears to be a delicate balance, crucial for advancing patient care while upholding ethical standards. The integration of AI in oncology presents remarkable opportunities, from precision medicine to early detection and treatment optimization. Yet, this innovative wave demands meticulous ethical considerations. Striking this balance involves mitigating biases in AI algorithms, ensuring transparency and accountability in decision-making, safeguarding patient privacy, and upholding informed consent and patient autonomy. This delicate equilibrium calls for a collective responsibility towards responsible AI development and implementation in oncology. It needs interdisciplinary collaboration among healthcare professionals, technologists, ethicists, policymakers, and patients. Clear ethical guidelines, continuous evaluation, and adaptation of AI systems are imperative to ensure that innovation aligns with ethical principles. In conclusion, the transformative potential of AI in cancer research and clinical care demands a conscientious approach. As we navigate this terrain, fostering innovation while anchoring it in ethical frameworks becomes paramount. The call to action lies in fostering a culture of responsible AI development and deployment in oncology, ensuring that technological strides amplify patient outcomes while upholding the ethical fabric of healthcare. This symbiotic relationship between innovation and ethics stands as the cornerstone for a future where AI augments oncology's capabilities responsibly and ethically.

References

1. Esteva, A., Robicquet, A., Ramsundar, B., et al. (2019). A guide to deep learning in healthcare. Nature Medicine, 25(1), 24–29. DOI: 10.1038/s41591-018-0316-z
2. Haenssle, H. A., Fink, C., Schneiderbauer, R., et al. (2018). Man against machine: diagnostic performance of a deep learning convolutional neural network for dermoscopic melanoma recognition in comparison to 58 dermatologists. Annals of Oncology, 29(8), 1836–1842. DOI: 10.1093/annonc/mdy166
3. Luo, G., Sun, G., Wang, K., et al. (2019). Artificial intelligence for the diagnosis of colorectal cancer: A comprehensive review. Expert Review of Gastroenterology & Hepatology, 13(2), 131–139. DOI: 10.1080/17474124.2019.1552393
4. Kourou, K., Exarchos, T. P., Exarchos, K. P., et al. (2015). Machine learning applications in cancer prognosis and prediction. Computational and Structural Biotechnology Journal, 13, 8–17. DOI: 10.1016/j.csbj.2014.11.005
5. Chartrand, G., Cheng, P. M., Vorontsov, E., et al. (2017). Deep learning: a primer for radiologists. Radiographics, 37(7), 2113–2131. DOI: 10.1148/rg.2017170077 Esteva, A., Kuprel, B., Novoa, R. A., et al. (2017). Dermatologist-level classification of skin cancer with deep neural networks. Nature, 542(7639), 115–118. DOI: 10.1038/nature21056
6. Topol, E. J. (2019). High-performance medicine: the convergence of human and artificial intelligence. Nature Medicine, 25(1), 44–56. DOI: 10.1038/s41591-018-0300-7
7. Gao, J., Aksoy, B. A., Dogrusoz, U., et al. (2013). Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Science Signaling, 6(269), pl1. DOI: 10.1126/scisignal.2004088

8. Lundberg, S. M., Lee, S. I. (2017). A unified approach to interpreting model predictions. Advances in Neural Information Processing Systems, 30, 4765–4774. PDF
9. Huang, C., Mezencev, R., McDonald, J. F., et al. (2011). Identification of mRNA biomarkers associated with PTSD in military veterans. BMC Medical Genomics, 4(1), 1–9. DOI: 10.1186/1755-8794-4-1
10. Krizhevsky, A., Sutskever, I., Hinton, G. E. (2012). ImageNet classification with deep convolutional neural networks. Advances in Neural Information Processing Systems, 25, 1097–1105. PDF
11. Zou, J., Huss, M., Abid, A., et al. (2019). A primer on deep learning in genomics. Nature Genetics, 51(1), 12–18. DOI: 10.1038/s41588-018-0295-5
12. Shen, D., Wu, G., Suk, H.-I. (2017). Deep learning in medical image analysis. Annual Review of Biomedical Engineering, 19(1), 221–248. DOI: 10.1146/annurev-bioeng-071516-044442
13. Doshi-Velez, F., Kim, B. (2017). Towards a rigorous science of interpretable machine learning. arXiv preprint arXiv:1702.08608. PDF
14. Ching, T., Himmelstein, D. S., Beaulieu-Jones, B. K., et al. (2018). Opportunities and obstacles for deep learning in biology and medicine. Journal of the Royal Society Interface, 15(141), 20170387. DOI: 10.1098/rsif.2017.0387 Rajkomar, A., Dean, J., Kohane, I. (2019). Machine learning in medicine. The New England Journal of Medicine, 380(14), 1347–1358. DOI: 10.1056/NEJMra1814259
15. Litjens, G., Kooi, T., Bejnordi, B. E., et al. (2017). A survey on deep learning in medical image analysis. Medical Image Analysis, 42, 60–88. DOI: 10.1016/j.media.2017.07.005
16. Chen, J. H., Asch, S. M. (2017). Machine learning and prediction in medicine: beyond the peak of inflated expectations. JAMA Internal Medicine, 177(1), 108–109. DOI: 10.1001/jamainternmed.2016.8297
17. Wang, S., Summers, R. M. (2012). Machine learning and radiology. Medical Image Analysis, 16(5), 933–951. DOI: 10.1016/j.media.2012.02.005
18. Rumsfeld, J. S., Joynt, K. E., Maddox, T. M. (2016). Big data analytics to improve cardiovascular care: promise and challenges. Nature Reviews Cardiology, 13(6), 350–359. DOI: 10.1038/nrcardio.2016.42
19. Weng, S. F., Reps, J., Kai, J., et al. (2017). Can machine-learning improve cardiovascular risk prediction using routine clinical data? PLOS ONE, 12(4), e0174944. DOI: 10.1371/journal.pone.0174944
20. Char, D. S., Shah, N. H., Magnus, D. (2018). Implementing machine learning in health care—addressing ethical challenges. New England Journal of Medicine, 378(11), 981–983. DOI: 10.1056/NEJMp1714229
21. Beam, A. L., Kohane, I. S. (2018). Big data and machine learning in health care. JAMA, 319(13), 1317–1318. DOI: 10.1001/jama.2017.18391 Oh, S., Kim, J. H., Choi, S. W., et al. (2021). Ethical considerations in the era of artificial intelligence in oncology. Cancer Medicine, 10(17), 5807–5821. DOI: 10.1002/cam4.4126
22. Ghassemi, M., Naumann, T., Schulam, P., et al. (2018). A review of challenges and opportunities in machine learning for health. AMIA Joint Summits on Translational Science Proceedings, 2018, 191–200. PubMed
23. Char, D. S., Shah, N. H. (2017). A practical guide to building ethical AI in healthcare. Harvard Data Science Review, 1(1). DOI: 10.1162/99608f92.f1ad3c64
24. Cohen, I. G., Amarasingham, R., Shah, A., et al. (2019). The legal and ethical concerns that arise from using complex predictive analytics in health care. Health Affairs, 38(3), 493–497. DOI: 10.1377/hlthaff.2018.05147
25. Vayena, E., Blasimme, A. (2017). Health research with big data: time for systemic oversight. The Journal of Law, Medicine & Ethics, 45(3), 395–403. DOI: 10.1177/1073110517734932
26. Price, W. N., Cohen, I. G. (2019). Privacy in the age of medical big data. Nature Medicine, 25(1), 37–43. DOI: 10.1038/s41591-018-0272-7

27. Char, D. S., Shah, N. H. (2018). An evidence-based approach to interactive machine learning for clinical decision support systems. AMIA Annual Symposium Proceedings, 2018, 320–329. PubMed
28. Sarwal, A., Sarwal, T., Fenech, M. (2019). Artificial intelligence and big data in cancer management: Challenges and opportunities. Advances in Experimental Medicine and Biology, 1168, 145–156. DOI: 10.1007/978-3-030-24115-4_10
29. Cabitza, F., Rasoini, R., Gensini, G. F. (2017). Unintended consequences of machine learning in medicine. JAMA, 318(6), 517–518. DOI: 10.1001/jama.2017.7797
30. Kumar, A., Choudhary, P., Kumari, R., et al. (2020). Ethical challenges of artificial intelligence in healthcare. Annals of Phytomedicine, 9(1), 84–88. ResearchGate
31. Obermeyer, Z., Emanuel, E. J. (2016). Predicting the future — big data, machine learning, and clinical medicine. The New England Journal of Medicine, 375(13), 1216–1219. DOI: 10.1056/NEJMp1606181
32. Rajkomar, A., Dean, J., Kohane, I. (2019). Machine learning in medicine. The New England Journal of Medicine, 380(14), 1347–1358. DOI: 10.1056/NEJMra1814259
33. Beam, A. L., Kohane, I. S. (2018). Big data and machine learning in health care. JAMA, 319(13), 1317–1318. DOI: 10.1001/jama.2017.18391
34. Char, D. S., Shah, N. H. (2017). A practical guide to building ethical AI in healthcare. Harvard Data Science Review, 1(1). DOI: 10.1162/99608f92.f1ad3c64
35. Topol, E. J. (2019). High-performance medicine: the convergence of human and artificial intelligence. Nature Medicine, 25(1), 44–56. DOI: 10.1038/s41591-018-0300-7
36. Char, D. S., Shah, N. H. (2017). A practical guide to building ethical AI in healthcare. Harvard Data Science Review, 1(1). DOI: 10.1162/99608f92.f1ad3c64
37. Bates, D. W., Landman, A., Levine, D. M. (2019). Health apps and health policy: what is needed? JAMA, 320(19), 1975–1976. DOI: 10.1001/jama.2019.15066
38. Vayena, E., Blasimme, A. (2017). Health research with big data: time for systemic oversight. The Journal of Law, Medicine & Ethics, 45(3), 395–403. DOI: 10.1177/1073110517734932
39. Beam, A. L., Kohane, I. S. (2018). Big data and machine learning in health care. JAMA, 319(13), 1317–1318. DOI: 10.1001/jama.2017.18391
40. Rajkomar, A., Dean, J., Kohane, I. (2019). Machine learning in medicine. The New England Journal of Medicine, 380(14), 1347–1358. DOI: 10.1056/NEJMra1814259
41. Hawkins, J. B., Clement, M. E., Evans, D. P. (2020). Understanding and improving computational study design and analysis in oncology. JCO Clinical Cancer Informatics, 4, 289–297. DOI: 10.1200/CCI.19.00163
42. Zhang, X., Zhao, J., LeCun, Y. (2018). Understanding deep learning requires rethinking generalization. arXiv preprint arXiv:1611.03530. PDF
43. Miotto, R., Wang, F., Wang, S., et al. (2018). Deep learning for healthcare: review, opportunities, and challenges. Briefings in Bioinformatics, 19(6), 1236–1246. DOI: 10.1093/bib/bbx044
44. Obermeyer, Z., Emanuel, E. J. (2016). Predicting the future — big data, machine learning, and clinical medicine. The New England Journal of Medicine, 375(13), 1216–1219. DOI: 10.1056/NEJMp1606181
45. Shah, N. H., Milstein, A., Bagley, T. P. (2019). Making machine learning models clinically useful. JAMA, 322(14), 1351–1352. DOI: 10.1001/jama.2019.11186
46. Beam, A. L., Kohane, I. S. (2018). Big data and machine learning in health care. JAMA, 319(13), 1317–1318. DOI: 10.1001/jama.2017.18391